Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma
CTR20211512Phase 3Active
- Sponsor
- Akeso, Inc.
- Start
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of penpulimab in nasopharyngeal carcinoma (NPC), sponsored by Akeso, Inc.. Started Aug 2021; status: active.
02
Drugs
penpulimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on CTR20211512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211512.